Evercore ISI Shines Some Light on Rocket Pharmaceuticals (RCKT) Regulatory Update

Evercore ISI analyst Joshua Schimmer reiterated an Outperform rating and $75.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).

The analyst comments "I caught up with RCKT management after this morning’s Danon gene therapy regulatory update. Seems like another “December gift” for an over-reaction to an encouraging update. The press release comes across as somewhat noncommittal in terms of pivotal trial design– and is impacting the stock today. It sounds as though the PR wording reflects the need to check the box and finalize the study design with FDA after ‘agreement-in-principle’ as opposed to meaningful uncertainty around key trial design elements."

For an analyst ratings summary and ratings history on Rocket Pharmaceuticals click here. For more ratings news on Rocket Pharmaceuticals click here.

Shares of Rocket Pharmaceuticals closed at $22.30 yesterday.

You May Also Be Interested In

• Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation
• Broadridge Financial (BR) PT Raised to $180 at UBS, Neutral Rating Maintained
• ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim